Dr. Mark Kiel presents the biomarker selection process and results for the first comprehensive evidence-based Pan-Hematopoietic Malignancy Gene Panel using the Mastermind Genomic Search Engine.
The single most time-consuming component of designing a new gene panel is selecting the target biomarkers associated with the specific set of diseases. Often, target selection is done by a combination of design-by-committee, competitive analysis, and time-consuming literature research. The result of this ad-hoc process is typically an incomplete list of biomarkers that isn’t backed up by references in the scientific literature.
Genomenon has introduced an evidence-based target identification process that uses the Mastermind Genomic Search Engine database to objectively correlate genes and genetic variants with the quality and frequency of citations from the scientific literature. This approach produces a list of comprehensive candidate biomarkers associated with a specific disease, with reference citations for each biomarker-disease association.
In this webinar, Genomenon CSO and co-founder Dr. Mark Kiel walks through the evidence-based biomarker selection process, including:
- How to find candidate genes for your panel based on the quality and frequency of high impact literature citations
- How to refine the gene list based on the specific goals for your panel – e.g. therapeutic, prognostic or diagnostic literature citations
- Selecting the right biomarker candidates to create your evidence-based gene panel, fully annotated with literature citations
Dr. Kiel demonstrates how the process can be applied to automate gene panel design, using hematopoietic malignancies as a representative example.
To receive a white paper documenting the process for the Pan-Hematopoietic Panel, including the curated list of over 300 gene targets for lymphoma and leukemia, with associated literature citations for each target, click here.